샘플 요청 목록

 카트 문의
시장보고서
상품코드
1737293

신경병증성 통증 시장

Neuropathic Pain
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 386 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

신경병증성 통증 세계 시장은 2030년까지 107억 달러에 달할 전망

2024년에 83억 달러로 추정되는 신경병증성 통증 세계 시장은 2024년부터 2030년까지 CAGR 4.3%로 성장하여 2030년에는 107억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 항우울제는 CAGR 5.4%를 기록하며 분석 기간 종료시에는 39억 달러에 달할 것으로 예측됩니다. 항경련제 부문의 성장률은 분석 기간 동안 CAGR 2.9%로 추정됩니다.

미국 시장은 23억 달러로 추정, 중국은 CAGR 8.1%로 성장 예측

미국의 신경병증성 통증 시장은 2024년에 23억 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 분석 기간인 2024-2030년 CAGR 8.1%로 2030년까지 22억 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 1.7%와 3.4%로 예측됩니다. 유럽에서는 독일이 CAGR 2.5%로 성장할 것으로 예측됩니다.

세계의 신경병증성 통증 시장 - 주요 동향과 촉진요인 정리

신경병증성 통증의 인식과 치료가 만성 통증 관리에서 중요한 모멘텀이 되는 이유는 무엇일까?

신경병증성 통증은 신경 손상이나 기능 장애로 인해 발생하는 복잡하고 종종 쇠약하게 만드는 만성 통증으로 삶의 질, 정신건강, 의료 서비스 이용 등에 큰 영향을 미치는 심각한 임상 문제로 대두되고 있습니다. 조직 손상이나 염증으로 인한 통각수용성 통증과 달리, 신경병증성 통증은 말초신경계 또는 중추신경계의 병변으로 인해 발생하며, 종종 작열감, 통증, 전기충격과 같은 감각, 또는 감각과민을 특징으로 합니다. 흔한 원인으로는 당뇨병성 신경장애, 대상포진 후 신경통, 화학요법으로 인한 신경장애, 다발성 경화증, 척수손상, 삼차신경통 등이 있습니다.

당뇨병, 암 생존율, 신경장애의 유병률 증가는 전 세계적으로 신경병증성 통증 진단의 급증에 기여하고 있습니다. 그러나 신경병증성 통증은 자각적 특성과 기존 진통제에 대한 내성으로 인해 진단과 치료가 제대로 이루어지지 않는 경우가 많습니다. 임상 가이드라인에서는 조기 발견과 약리학적, 중재적, 심리학적 방법을 포함한 다각적인 치료가 점점 더 강조되고 있습니다. 임상의와 환자 모두의 인식이 높아짐에 따라 효과적이고 내약성이 좋은 약물요법에 대한 수요가 가속화되고 있으며, 이는 신경병증성 통증 치료 시장의 성장을 촉진하고 있습니다.

약리학적 발전과 맞춤형 치료 전략은 신경병증성 통증의 치료 결과를 어떻게 개선하고 있는가?

현재 신경병증성 통증에 대한 약리학적 치료는 가바펜티노이드(가바펜틴, 프레가발린), 세로토닌 노르에피네프린 재흡수 억제제(SNRI), 삼환계 항우울제(TCA), 국소 리도카인 또는 캡사이신, 그리고 최후의 수단으로 오피오이드 등이 있습니다. 이들 치료법은 신경 신호 전달의 조절, 신경전달물질의 방출 억제, 통증 수용체의 탈감작을 목적으로 합니다. 그러나 효과의 편차가 있고, 내약성에 문제가 있으며, 의존성의 위험이 있어 대체요법이나 보조요법에 대한 관심이 높아지고 있습니다.

최근의 기술 혁신으로는 나트륨 채널 차단제(라코사미드 등), 칼슘 채널 조절제, 카나비노이드 기반 치료제, 통증 특이적 수용체를 표적으로 하는 유전자 치료 등이 있습니다. 경두개 자기자극(TMS), 경피적 전기신경자극(TENS)과 같은 비침습적 신경조절 기술은 멀티모달 통증 관리 프로토콜에 통합되고 있습니다. 통증 표현형, 정량적 감각 검사, 디지털 통증 추적과 같은 치료법의 발전으로 보다 맞춤화되고 역동적인 치료 전략이 가능해졌습니다. 이러한 발전은 만성 신경병성 통증에 대한 접근 방식을 재정의하고 있으며, 시행착오적인 처방에서 근거에 기반한 환자별 치료 경로로 전환하고 있습니다.

신경병증성 통증 시장을 주도하는 환자 집단과 지역 의료 시스템은?

신경병증성 통증 시장을 주도하는 주요 환자군으로는 당뇨병 환자(특히 통증을 동반한 당뇨병성 말초신경병증 환자), 화학요법을 받고 있는 암 생존자, 뇌졸중 후 또는 수술 후 신경 손상을 입은 노인 환자, 척수장애 및 다발성 경화증 환자 등이 있습니다. 성별에 따라 차이가 있으며, 여성이 통증의 강도와 치료 저항성이 더 높은 것으로 보고되고 있습니다. 만성 통증의 유병률은 고령화 사회에서 현저하게 높으며, 인구통계학적 불균형 지역에서의 수요가 더욱 증가하고 있습니다.

북미는 높은 의료비 지출, 만성질환 유병률, 통증관리 전문의에 대한 접근성이 높아 시장을 선도하고 있습니다. 유럽은 강력한 임상 가이드라인과 비오피오이드 진통제 솔루션에 대한 관심이 높아지면서 그 뒤를 잇고 있습니다. 아시아태평양은 급속한 도시화, 당뇨병 유병률 증가, 인도, 중국, 일본 등의 국가에서 전문 의료 서비스에 대한 접근성 확대로 인해 괄목할 만한 성장을 보이고 있습니다. 라틴아메리카와 아프리카 일부 지역에서는 여전히 미진단 시장이 남아 있지만, 원격의료, 모바일 건강 앱, 만성 통증 문해력 향상을 위한 사회 인식 개선 캠페인을 통해 성장이 예상됩니다.

신경병증성 통증 시장의 장기적인 혁신과 상업적 확장의 원동력은 무엇인가?

신경병증성 통증 시장의 성장은 질병 발생률의 증가, 진단 능력의 향상, 근본적인 신경 기능 장애를 치료하는 표적 치료의 혁신에 의해 촉진되고 있습니다. 오피오이드 관리(opioid stewardship)가 전 세계적으로 우선순위로 떠오르면서 안전성과 효능이 우수한 대체 진통제에 대한 투자가 증가하고 있습니다. R&D 파이프라인은 생물학적 제제, 이온 채널 조절제, RNA 기반 치료제, 신경 염증 및 통증 감작 경로를 표적으로 하는 단클론항체 등으로 확대되고 있습니다.

규제 당국은 특히 희귀 또는 치료 저항성 통증 증후군과 같은 미충족 수요를 충족하는 치료제의 경우, 신속한 경로를 통해 신제품 승인을 지원하고 있습니다. 동반진단과 디지털 건강의 통합은 역동적인 용량 증량 및 더 나은 순응도 모니터링을 가능하게 하고 있습니다. 만성 통증관리가 다학제적 접근이 되면서 정밀의료, 통합치료, 환자중심의 치료결과를 넘어 증상억제를 넘어선 환자중심의 치료로 전환됨에 따라 신경병증성 통증 시장은 지속적인 성장을 이룰 수 있는 여건을 갖추고 있습니다.

부문

약물 종류(항우울제, 항경련제, 오피오이드, 캡사이신, 기타 약물 종류별), 적응증(당뇨병성 신경병증, 척추관 협착증, 화학요법 유발성 말초신경병증, 기타 적응증), 유통 채널(병원 약국, 드럭스토어·소매 약국, 온라인 약국)

조사 대상 기업 사례(총 44개사)

  • AbbVie Inc.
  • Akelos Inc.
  • Averitas Pharma, Inc.
  • BioLineRx Ltd.
  • Bristol-Myers Squibb Company
  • Dogwood Therapeutics
  • Eli Lilly and Company
  • GlaxoSmithKline plc(GSK)
  • Grunenthal GmbH
  • Johnson & Johnson
  • Lexicon Pharmaceuticals, Inc.
  • Mallinckrodt Pharmaceuticals
  • Neuropathix Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • SiteOne Therapeutics
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Trevena, Inc.
  • Vertex Pharmaceuticals Incorporated

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 인위적인 매출원가 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

Global Industry Analysts는 세계 주요 수석 이코노미스트(1,4,949명), 싱크탱크(62개 기관), 무역 및 산업 단체(171개 기관)의 전문가들의 의견을 면밀히 검토하여 생태계에 미치는 영향을 평가하고 새로운 시장 현실에 대응하고 있습니다. 모든 주요 국가의 전문가와 경제학자들이 관세와 그것이 자국에 미치는 영향에 대한 의견을 추적 조사하고 있습니다.

Global Industry Analysts는 이러한 혼란이 향후 2-3개월 내에 마무리되고 새로운 세계 질서가 보다 명확하게 확립될 것으로 예상하고 있으며, Global Industry Analysts는 이러한 상황을 실시간으로 추적하고 있습니다.

2025년 4월 : 협상 단계

이번 4월 보고서에서는 관세가 세계 시장 전체에 미치는 영향과 지역별 시장 조정에 대해 소개합니다. 당사의 예측은 과거 데이터와 진화하는 시장 영향요인을 기반으로 합니다.

2025년 7월 : 최종 관세 재설정

고객님들께는 각 국가별 최종 리셋이 발표된 후 7월에 무료 업데이트 버전을 제공해 드립니다. 최종 업데이트 버전에는 명확하게 정의된 관세 영향 분석이 포함되어 있습니다.

상호 및 양자 간 무역과 관세의 영향 분석:

미국 <> 중국 <> 멕시코 <> 캐나다 <> EU <> 일본 <> 인도 <> 기타 176개국

업계 최고의 이코노미스트 : Global Industry Analysts의 지식 기반은 국가, 싱크탱크, 무역 및 산업 단체, 대기업, 그리고 세계 계량 경제 상황의 전례 없는 패러다임 전환의 영향을 공유하는 분야별 전문가 등 가장 영향력 있는 수석 이코노미스트 그룹을 포함한 14,949명의 이코노미스트를 추적하고 있습니다. 16,491개 이상의 보고서 대부분에 마일스톤에 기반한 2단계 출시 일정을 적용하고 있습니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

ksm 25.06.12

Global Neuropathic Pain Market to Reach US$10.7 Billion by 2030

The global market for Neuropathic Pain estimated at US$8.3 Billion in the year 2024, is expected to reach US$10.7 Billion by 2030, growing at a CAGR of 4.3% over the analysis period 2024-2030. Antidepressants, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$3.9 Billion by the end of the analysis period. Growth in the Anticonvulsant segment is estimated at 2.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.3 Billion While China is Forecast to Grow at 8.1% CAGR

The Neuropathic Pain market in the U.S. is estimated at US$2.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.2 Billion by the year 2030 trailing a CAGR of 8.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 3.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.5% CAGR.

Global Neuropathic Pain Market - Key Trends & Drivers Summarized

Why Is Neuropathic Pain Recognition and Treatment Gaining Critical Momentum in Chronic Pain Management?

Neuropathic pain, a complex and often debilitating form of chronic pain caused by nerve damage or dysfunction, has emerged as a significant clinical concern with far-reaching implications for quality of life, mental health, and healthcare utilization. Unlike nociceptive pain, which results from tissue injury or inflammation, neuropathic pain arises from lesions in the peripheral or central nervous system and is often characterized by burning, tingling, electric shock-like sensations, or hypersensitivity. Common causes include diabetic neuropathy, postherpetic neuralgia, chemotherapy-induced neuropathy, multiple sclerosis, spinal cord injuries, and trigeminal neuralgia.

The rising prevalence of diabetes, cancer survivorship, and neurological disorders is contributing to a global surge in neuropathic pain diagnoses. However, due to its subjective nature and resistance to conventional analgesics, neuropathic pain is frequently underdiagnosed and undertreated. Clinical guidelines increasingly emphasize early identification and multidimensional therapy involving pharmacological, interventional, and psychological modalities. As awareness grows among both clinicians and patients, the demand for effective and well-tolerated pharmacotherapies is accelerating, propelling the growth of the neuropathic pain treatment market.

How Are Pharmacological Advances and Personalized Treatment Strategies Improving Outcomes in Neuropathic Pain?

Current pharmacological treatments for neuropathic pain include first-line agents such as gabapentinoids (gabapentin, pregabalin), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), topical lidocaine or capsaicin, and opioids as a last resort. These therapies aim to modulate neural signaling, inhibit neurotransmitter release, or desensitize pain receptors. However, variable efficacy, tolerability issues, and the risk of dependence have spurred interest in alternative and adjunctive therapies.

Recent innovations include sodium channel blockers (e.g., lacosamide), calcium channel modulators, cannabinoid-based therapies, and gene therapy targeting pain-specific receptors. Non-invasive neuromodulation techniques-such as transcranial magnetic stimulation (TMS) and transcutaneous electrical nerve stimulation (TENS)-are being incorporated into multimodal pain management protocols. Advances in pain phenotyping, quantitative sensory testing, and digital pain tracking are enabling more tailored and dynamic treatment strategies. These developments are redefining how chronic neuropathic pain is approached-shifting from trial-and-error prescribing to evidence-informed, patient-specific care pathways.

Which Patient Cohorts and Regional Healthcare Systems Are Driving the Neuropathic Pain Market?

Key patient groups driving the neuropathic pain market include individuals with diabetes (especially those with painful diabetic peripheral neuropathy), cancer survivors undergoing chemotherapy, elderly patients with post-stroke or post-surgical nerve damage, and individuals with spinal disorders or multiple sclerosis. Gender disparities are also observed, with women reporting higher pain intensity and treatment resistance. Chronic pain prevalence is notably higher in aging populations, further intensifying demand in regions with demographic imbalances.

North America leads the market due to high healthcare spending, widespread chronic disease burden, and robust access to pain management specialists. Europe follows with strong clinical guidelines and a growing focus on non-opioid pain control solutions. Asia-Pacific is experiencing significant growth due to rapid urbanization, rising diabetes prevalence, and expanding access to specialty care in countries like India, China, and Japan. Latin America and parts of Africa remain underdiagnosed markets but are expected to grow through telemedicine, mobile health apps, and public awareness campaigns targeting chronic pain literacy.

What Is Powering Long-Term Innovation and Commercial Expansion in the Neuropathic Pain Market?

The growth in the neuropathic pain market is fueled by increasing disease incidence, improved diagnostic capabilities, and innovation in targeted therapies that address underlying neurological dysfunction. As opioid stewardship becomes a global priority, investment is flowing into alternative analgesics with better safety and efficacy profiles. R&D pipelines are expanding to include biologics, ion channel modulators, RNA-based therapeutics, and monoclonal antibodies that target neural inflammation and pain sensitization pathways.

Regulatory bodies are supporting novel product approvals through expedited pathways, especially for therapies addressing unmet needs in rare or treatment-refractory pain syndromes. Companion diagnostics and digital health integrations are enabling dynamic dose titration and better adherence monitoring. As chronic pain management becomes a multidisciplinary endeavor, the neuropathic pain market is poised for sustained growth-anchored by a shift toward precision medicine, integrated care, and patient-centric outcomes that extend beyond mere symptom suppression.

SCOPE OF STUDY:

The report analyzes the Neuropathic Pain market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Antidepressants, Anticonvulsant, Opioids, Capsaicin, Other Drug Classes); Indication (Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy, Other Indications); Distribution Channel (Hospital Pharmacies, Drugs Stores & Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • AbbVie Inc.
  • Akelos Inc.
  • Averitas Pharma, Inc.
  • BioLineRx Ltd.
  • Bristol-Myers Squibb Company
  • Dogwood Therapeutics
  • Eli Lilly and Company
  • GlaxoSmithKline plc (GSK)
  • Grunenthal GmbH
  • Johnson & Johnson
  • Lexicon Pharmaceuticals, Inc.
  • Mallinckrodt Pharmaceuticals
  • Neuropathix Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • SiteOne Therapeutics
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Trevena, Inc.
  • Vertex Pharmaceuticals Incorporated

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Neuropathic Pain - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Diabetes and Chemotherapy-Induced Neuropathy Propels Demand for Neuropathic Pain Therapies
    • Emergence of Novel Ion Channel Modulators Expands Treatment Portfolio and Market Penetration
    • Regulatory Approvals of Dual-Mechanism Analgesics Strengthen Business Case for Neuropathic Pain Drugs
    • Advancements in Peripheral Nerve Stimulation Techniques Drive Adoption of Device-Based Therapies
    • Increased Recognition of Central Sensitization Pathways Spurs Innovation in Drug Targets
    • Availability of Extended-Release Formulations Enhances Patient Adherence and Therapy Outcomes
    • Growing Integration of Neuropathic Pain Assessment Tools Strengthens Personalized Treatment Approaches
    • Rising Geriatric Population Sustains Growth in Age-Associated Neuropathic Pain Management
    • Expansion of Off-Label Prescriptions Creates Market Opportunities for Existing CNS Drugs
    • Integration of Digital Pain Tracking Platforms Throws the Spotlight on Telehealth-Based Monitoring
    • Surge in Research Funding for Pain Pathophysiology Accelerates Drug Discovery Pipelines
    • Adoption of Combination Pharmacotherapy Enhances Efficacy in Treatment-Resistant Cases
    • Stringent Opioid Regulation Frameworks Drive Shift Toward Non-Opioid Neuropathic Pain Solutions
    • Clinical Emphasis on Early Diagnosis Supports Preventive Pharmacological Interventions
    • Rising Demand for Non-Addictive Analgesics Spurs Interest in Novel Drug Mechanisms
    • Availability of Neuropathic Pain Biomarkers Strengthens Role of Predictive Diagnostics
    • Challenges in Regulatory Approval Timelines Pose Delays for First-in-Class Therapies
    • Growing Use of CBD-Derived Formulations Expands Alternative Pain Management Landscape
    • Integration of Artificial Intelligence in Drug Repurposing Enhances Pipeline Diversification
    • Increased Patient Awareness Through Advocacy Campaigns Generates Therapy Demand
    • Regional Variability in Pain Management Guidelines Creates Fragmentation in Market Penetration
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Neuropathic Pain Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Neuropathic Pain by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Neuropathic Pain by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Neuropathic Pain by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Antidepressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Antidepressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Antidepressants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Anticonvulsant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Anticonvulsant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Anticonvulsant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Opioids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Opioids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Opioids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Capsaicin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Capsaicin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Capsaicin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Drugs Stores & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Drugs Stores & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Drugs Stores & Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Diabetic Neuropathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Diabetic Neuropathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Diabetic Neuropathy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Spinal Stenosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Spinal Stenosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Spinal Stenosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Chemotherapy-Induced Peripheral Neuropathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Chemotherapy-Induced Peripheral Neuropathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Chemotherapy-Induced Peripheral Neuropathy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Neuropathic Pain Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Canada 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Canada 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
  • JAPAN
    • Neuropathic Pain Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Japan 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Japan 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Japan 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
  • CHINA
    • Neuropathic Pain Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 68: China Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: China 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: China 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: China 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
  • EUROPE
    • Neuropathic Pain Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Neuropathic Pain by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Neuropathic Pain by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Neuropathic Pain by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Europe 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Europe 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
  • FRANCE
    • Neuropathic Pain Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 89: France Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: France 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: France 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: France 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
  • GERMANY
    • Neuropathic Pain Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Germany 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Germany 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Germany 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Italy 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Italy 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Italy 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Neuropathic Pain Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 116: UK Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: UK 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: UK 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: UK 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Spain 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Spain 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Spain Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Spain 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Russia 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Russia 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Russia Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Russia 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Rest of Europe 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Neuropathic Pain Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Neuropathic Pain by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Neuropathic Pain by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Neuropathic Pain by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Asia-Pacific 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Neuropathic Pain Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Australia 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Australia 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 170: Australia Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Australia Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Australia 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
  • INDIA
    • Neuropathic Pain Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 173: India Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: India 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: India 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 179: India Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: India Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: India 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: South Korea 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: South Korea 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 188: South Korea Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: South Korea Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: South Korea 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Asia-Pacific Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Asia-Pacific 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Neuropathic Pain Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Neuropathic Pain by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Neuropathic Pain by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Neuropathic Pain by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Latin America 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Latin America 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Latin America Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Latin America 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Argentina 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Argentina 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 218: Argentina Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Argentina Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Argentina 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Brazil 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Brazil 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 227: Brazil Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Brazil Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Brazil 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Mexico 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Mexico 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 236: Mexico Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Mexico Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Mexico 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Latin America Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Rest of Latin America 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Neuropathic Pain Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Neuropathic Pain by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Neuropathic Pain by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Neuropathic Pain by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Middle East 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Middle East 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Middle East Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Middle East 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Iran 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Iran 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 266: Iran Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Iran Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Iran 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Israel 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Israel 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 275: Israel Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Israel Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Israel 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Saudi Arabia Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Saudi Arabia 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: UAE 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: UAE 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 293: UAE Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: UAE Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: UAE 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Middle East Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Rest of Middle East 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030
  • AFRICA
    • Neuropathic Pain Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Neuropathic Pain by Drug Class - Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Africa 15-Year Perspective for Neuropathic Pain by Drug Class - Percentage Breakdown of Value Sales for Antidepressants, Anticonvulsant, Opioids, Capsaicin and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Neuropathic Pain by Distribution Channel - Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 310: Africa 15-Year Perspective for Neuropathic Pain by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drugs Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 311: Africa Recent Past, Current & Future Analysis for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Africa Historic Review for Neuropathic Pain by Indication - Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 313: Africa 15-Year Perspective for Neuropathic Pain by Indication - Percentage Breakdown of Value Sales for Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy and Other Indications for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제